The impact of genome-wide histocompatibility on liver transplantation outcomes

Semenova M¹, Liukkonen V^{2,3}, Markkinen S¹, Färkkilä M², Nordin A⁴, Partanen J¹, Åberg F⁴, Hyvärinen K^{1*}

- Finnish Red Cross Blood Service, Research and Development, Helsinki, Finland
 University of Helsinki, Faculty of Medicine, Helsinki, Finland
 - 3. North Carelia Central Hospital, Gastroenterology, Joensuu, Finland
- 4. Transplantation and Liver Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

Short title: Genome-wide mismatches in liver transplantation

Corresponding author: Kati Hyvärinen, PhD, Associate professor Finnish Red Cross Blood Service Research and Development Biomedicum Helsinki 1, Haartmaninkatu 8, 00290 Helsinki, FINLAND Phone +358 40 920 3083 kati.hyvarinen@bloodservice.fi

Abbreviations

aHR, adjusted hazard ratio

- AR, Acute rejection
- CI, Confidence interval
- CHR, Chromosome
- DNA, Deoxyribonucleic acid
- DSA, Donor-specific antibody
- eQTL, Expression quantitative trait loci
- FDR, False discovery rate
- GSA, Global screening array
- HLA, Human leukocyte antigen
- HSCT, hematopoietic stem cell transplantation
- IQR, Interquartile range
- LCL, Lateral collateral ligament
- LT, Liver transplantation
- MAF, Minor allele frequency
- MD, Multi-Disease
- MHC, Major histocompatibility complex
- NA, Not available
- POS, Position
- QC, Quality control

1 ABSTRACT

Liver transplantation (LT) is the standard treatment for end-stage liver disease. The
role of human leukocyte antigen (HLA) matching in LT remains unclear. Immunologic
allograft injury and rejection continue to be concerns, especially when minimizing
immunosuppression. While HLA matching currently has no established role in LT, nonHLA compatibility has attracted increased attention.

We compared 666 LT recipient-donor pairs and identified genomic mismatches
outside HLA segment in different protein groups and 40 common gene deletions. We
evaluated the associations with LT outcomes using adjusted Cox models.

10 Quartiles of missense variants coding for all proteins were associated with late rejection with an adjusted hazard ratio (aHR) 0.812 (95% confidence interval [CI]: 11 0.674-0.977, P-value 0.028). Deletion mismatches tagged by rs11985201 and 12 rs2342606 were associated with AR with aHR 1.483 (95% CI: 1.066-2.062, P-value 13 0.019) and aHR 1.373 (95% CI: 1.011-1.865, P-value 0.042), respectively. Deletion 14 mismatch in rs2174926 was associated with graft loss with aHR 2.332 (95% CI: 1.145-15 4.752, P-value 0.020) and in rs1944862 with late rejection with aHR 2.341 (95% CI: 16 1.326–4.130, P-value 0.003). False detection rates <0.05 were not reached. 17

In conclusion, genome-wide mismatches may contribute to LT complications.However, robust large-scale studies are essential for validation.

20

21 Keywords

22 Acute rejection, late rejection, graft loss, overall survival, genome-wide

23 incompatibility.

24 INTRODUCTION

Liver transplantation (LT) is the standard treatment for end-stage liver disease, acute 25 liver failure and selected liver cancers. Survival after LT has improved in recent years, 26 and more than 60% of recipients now survive over 10 years¹. With modern 27 immunosuppression regimens, immunological complications, including acute rejection 28 (AR) or chronic rejection, rarely lead to graft loss, even though late AR has been 29 associated with inferior graft and recipient survival². Recognition of the potential role 30 antibodies (DSA)³, especially under immunosuppression donor-specific 31 of minimization, and reports of subclinical immunological damage and fibrosis in liver 32 allografts⁴ have revived interest in immunology in recent years, but majority of graft 33 losses results from non-immunological reasons⁵. 34

35

Cancer, cardiovascular events, renal failure and infections are the major reasons for mortality after LT and immunosuppressive medication predisposes recipients to such events⁵. Thus, minimizing immunosuppression to improve survival has become a major target in post-LT management⁶. As the risk of complications varies between individuals, individualized approach to immunosuppression management could improve post-LT outcomes.

The significance of human leucocyte antigens (HLA) is well-understood in 42 hematopoietic stem cell transplantation (HSCT)⁷ and kidney transplantation⁸. In 43 addition, in the last decade, mismatches between recipient and donor in genes located 44 outside the HLA segment has emerged as a novel histocompatibility factor in HSCT^{9,10} 45 and kidney transplantation^{11–15}. For example, according to a recent study, the kidney 46 allograft survival was influenced by incompatibility in genes outside HLA¹². In another 47 recent study, researchers stated that genomic mismatch at LIMS1 locus was 48 associated with rejection of the kidney allograft¹¹. 49

The effect of HLA compatibility on LT outcomes is still debated with studies showing mixed outcomes^{16,17} and matching is not used in organ allocation. There is a clear lack of data about the role of genome-wide compatibility in LT. Identifying novel risk factors for immunological and other important post-LT complications could help with risk stratification and individualized management¹⁸.

In the present study, we analyzed the association of genome-wide incompatibility and

time to any AR, late AR, graft loss and death in a LT cohort of 666 recipient-donor

57 pairs to identify novel genetic risk factors for LT outcomes.

58

59 STUDY SUBJECTS AND METHODS

60 Study cohort and design

The study conforms to the principles of the Declaration of Helsinki and has been approved by the ethics committee of Helsinki University Hospital (HUS/155/2021), the Finnish Medicines Agency Fimea (FIMEA/2021/004031), and Abdominal Center, Helsinki University Hospital (HUS/155/2021/68).

65 The characteristics of the recipients are described in Tables 1 and 2. The flow chart of the study cohort is presented in **Figure 1**. In total, 894 liver transplantation recipients 66 who had received a liver transplant between years 2000-2018 and their respective 67 first transplantation donors were included in the present study. The DNA samples of 68 both recipients and donors were extracted from whole blood samples at Finnish Red 69 Cross Blood Service, Helsinki. After exclusion of individuals lacking DNA samples, the 70 whole study cohort was divided into three different cohorts: Genotyping cohort 1 71 consisting of 286 donors, Genotyping cohort 2 including 30 recipients and 125 donors, 72 and Genotyping cohort 3 comprising 1202 individuals. Individuals who failed passing 73 the quality control (QC), who's pair was missing genotyping information and those 74 younger than 18 years old were excluded. 75

All ARs were biopsy confirmed according to BANFF-scheme¹⁹. Late rejection was determined as AR diagnosed over 90 days after the transplantation. Primary or secondary LT indication of primary sclerosing cholangitis, primary biliary cholangitis, or autoimmune hepatitis was categorized as autoimmune liver disease.

80

81 Genotyping and genotype imputation

Supplementary Figure 1 presents the flow of genetic variants in pre- and post imputation processes. Genotyping was performed at the Finnish Institute of Molecular
 Medicine, Helsinki, Finland. Cohort I was genotyped using Illumina Infinium[™] Global

Screening Array (GSA)-24 v3.0 BeadChip + Multi-Disease (MD) drop-in customized 85 with 34,191 Finnish variants. Cohorts II and III were genotyped using Illumina 86 Infinium[™] GSA-24 v2.0 + MD bead chip. Prior to genotype imputation, results in build 87 GRCh37 were lifted over to the GRCh38²⁰. Genotype imputation was performed with 88 Beagle v4.1 program utilizing THL Biobank's SISu v3 reference panel according to 89 al.21 90 Palta et https://www.protocols.io/view/genotype-imputation-workflow-v3-0xbgfijw?step=4&comment_id=86624. In post-imputation QC, individuals with missing 91 genotype >5% and variants with missing data rate >10%, minor allele frequency (MAF) 92 93 <1%, and imputation INFO score <0.6 were excluded. In total, 8,706,949 common variants were available for the analyses. 94

95

96 HLA imputation and eplet mismatches

Imputation of alleles of HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, and -DPB1 genes was
performed according to Ritari *et al.*²² utilizing R package HIBAG in RStudio version
3.6.3. (https://github.com/FRCBS/HLA-imputation).

HLA eplet mismatches between recipients and donors were calculated for imputed
 HLA-A, -B, -C, -DRB, -DQB, and -DPB alleles utilizing HLAMatchmaker
 (http://www.epitopes.net/)²³. HLA-A, -B, and -C alleles were matched using a <u>ABC</u>
 <u>Eplet Matching Program V4.0</u> and HLA-DRB, -DPB, -DQA, and -DQB alleles were
 matched using a <u>DRDQDP Eplet Matching Program V3.1</u> program. The programs
 were downloaded from <u>http://www.epitopes.net/downloads.html</u>.

106

107 Missense variant mismatch analyses

Prior to performing mismatch analyses, the variants coded on major histocompatibility 108 complex (MHC) region on chromosome 6 and both sex chromosomes were excluded, 109 leaving only autosomal non-HLA variants in the dataset. Figure 2 shows the flow of 110 variants. Functional annotation of variants was performed with Ensemble Variant 111 Effect Predictor²⁴ release 106 112 (https://www.ensembl.org/info/docs/tools/vep/script/index.html). Transcripts for all, 113 transmembrane and secreted proteins, transmembrane proteins, and liver-related 114 proteins were retrieved from UniProt 84 (<u>https://www.uniprot.org/</u>). Filtering operator 115

116 "consequence is missense_variants" was utilized. Term missense variant refers to a

nucleotide polymorphism changing the encoded amino acid in the protein.

- 118 The query strings for different protein groups were as follows:
- 119 1. Transmembrane and secreted proteins

(annotation:(type:transmem) OR locations:(location:"Secreted [SL-0243]") OR
 keyword:"Transmembrane [KW-0812]") AND reviewed:yes AND organism:"Homo
 sapiens (Human) [9606]"

123 2. Transmembrane proteins

(annotation:(type:transmem) OR keyword:"Transmembrane [KW-0812]") AND
 reviewed:yes AND organism:"Homo sapiens (Human) [9606]"

126 3. Liver-related proteins

annotation:(type:"tissue specificity" liver) AND reviewed:yes AND organism:"Homosapiens (Human) [9606]"

We compared recipient and donor genomes pairwise and calculated missense variant mismatch sums between the genomes for four different protein groups: missense variants coding for 1) all proteins, 2) transmembrane and secreted proteins, 3) transmembrane proteins only, 4) liver-related proteins.

Cox proportional hazards models were utilized to investigate the effect of missense 133 variant mismatches on time to AR, late rejection, graft loss, and overall survival. We 134 analyzed both missense variant mismatch sums and guartiles of missense variant 135 mismatch sums in each protein group. All models were adjusted with recipient and 136 137 donor sex, recipient and donor age, cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of transplantation, autoimmune liver disease, and initial 138 139 calcineurin inhibitor type. Censoring occurred on the end of the follow up time, retransplantation, or death. Kaplan-Meier plots were used to visualize the AR-, late 140 rejection-, graft loss-, death-free survival of the recipients. 141

142

143 **Deletion analyses**

The study protocol presented by Markkinen *et al.*²⁵ was followed. 40 deletion-tagging
 variants and their frequencies in the study cohort are presented in **Supplementary Table S1**. Deletion mismatch was defined as a situation where recipient is

homozygous for a deletion-tagging allele and receives a liver from a donor that is either
homozygous or heterozygous for the reference allele.

We analyzed the effect of homozygous mismatches in 40 deletion-tagging variants 149 using adjusted Cox proportional hazards models. Censoring occurred on re-150 transplantation, death or end of the follow up time. The dependent variables were time 151 to any AR, late AR, graft loss and death. We investigated the deletion-tagging variant 152 mismatches separately and quartiles of sum of deletion-tagging variant mismatches. 153 All models were adjusted with donor and recipient age, donor and recipient sex, cold 154 ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of transplantation, 155 autoimmune liver disease and initial calcineurin inhibitor type. Kaplan-Meier survival 156 curves were used to visualize the rejection-, graft loss- and death-and late rejection-157 158 free survival of the recipients. Full Cox models and Kaplan-Meier plots (Figures 3-6) are presented for variants with nominal P-values <0.05 and with n value of 159 160 homozygous deletion-tagging variant mismatches >10 (Supplementary Tables S1, S6-S9). 161

162

163 Expression quantitative trait loci results and regulatory element annotations

Expression quantitative trait loci (eQTL) results were searched for four deletion-164 tagging variants rs11985201, rs2342606, rs2174926, and rs1944862, all with p-165 FIVEx²⁶ before correction for multiple comparisons, using values <0.05 166 27 https://fivex.sph.umich.edu/ and eQTLGen phase 167 https://www.eqtlgen.org/phase1.html. Regulatory elements were identified utilizing 168 RegulomeDB²⁸ database https://regulomedb.org/regulome-search/. The Regulome 169 DB rank varies from 1(a-f)–7 and the score ranges from 0–1 (with 1 as the most reliable 170 result). Regulatory motifs and annotations were also explored using Haploreg²⁹ v4.2 171 tool https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php. 172

173

174 Other statistical analyses

Normality of variable distributions was evaluated using the Shapiro-Wilk normality test.
In **Tables 1 and 2**, the variation between outcome groups was analyzed using the
Pearson's chi-square test for categorical data (recipient gender, primary indication,

autoimmune liver disease and initial calcineurin inhibitor type) and the nonparametric

179 Mann-Whitney U-test for nonnormally distributed data (recipient age, follow-up time,

cold ischemia time, HLA eplet mismatch sum, HLA I eplet mismatch sum and HLA II

181 eplet mismatch sum). P-values <0.05 were considered statistically significant.

- 182 To counteract the multiple comparison problem in mismatch analyses, false discovery
- rate (FDR) was determined and FRD <0.05 was considered statistically significant.
- 184 All analyses were performed using in R v3.6.3³⁰.
- 185

186 Data and code availability

Individual genotype data are not publicly available due to restrictions issued by the
 ethical committee and current legislation in Finland that do not allow the distribution of
 pseudonymized personal data, including genetic and clinical data.

- 190 Analysis scripts are available at https://github.com/FRCBS XXXXXX.
- 191

192 **RESULTS**

193 Characteristic of the study population

194 Characteristics of the recipients in the study population are presented in **Tables 1 and** 195 **2**. During the follow up time (median interquartile range [IQR] 7 [4–12] years), of the 196 666 recipients, 42% experienced AR, 15% late rejection, 6% graft loss, and 24% died. 197 Women had AR more often than men (51% vs. 49%, P-value 0.029). The median 198 (IQR) time to AR was 21 (11–87) days. The median (IQR) time to late rejection was 199 11 (5–23) months. The median (IQR) time to graft loss was 34 (4–77) months and the 190 median (IQR) time to death was 3 (1–9) years.

201

202 Missense variant mismatch analyses

After the exclusion of sex chromosomes, MHC region, and non-missense variants, 28,225 missense variants were available for the mismatch analyses. Of these missense variants, 9,337 variants code for both transmembrane and secreted proteins, 6,963 variants for transmembrane proteins only, and 3,199 variants for liver-

related proteins (Figure 2). Table 3 shows results from Cox proportional hazards 207 models, both the sums and quartiles of missense variant mismatches. 208 Supplementary figure S2 displays the effect of quartiles of missense variant 209 mismatches of all proteins on late rejection -free survival. Supplementary Figure S3 210 shows the effect of quartiles of missense variant mismatches of transmembrane 211 proteins only on graft loss -free survival. All models were adjusted with recipient and 212 donor age, recipient and donor sex, cold ischemia time, HLA I eplet mismatch, HLA II 213 eplet mismatch, year of transplantation, autoimmune liver disease, and initial 214 215 calcineurin inhibitor type. We observed an association between both the sum and quartiles of mismatches in missense variants in all proteins and time to late rejection 216 (HR 0.998, 95% CI 0.996-0.999, P-value 0.011 and HR 0.812, 95% CI 0.674-0.977, 217 218 P-value 0.028, respectively).

219

220 Deletion analyses

The results from adjusted Cox proportional hazards models showed that a deletion

mismatch in variants rs11985201 and rs2342606 was associated with time to AR

with HR 1.483 (95% CI: 1.066–2.062, P-value 0.019, Supplementary Table S6,

224 Figure 3 and HR 1.373 (95% CI: 1.011–1.865, P-value 0.042, Supplementary

Table S7, Figure 4), respectively. In addition, time to late rejection was associated

with deletion mismatch in rs1944862 with HR 2.341 (95% CI: 1.326–4.130, P-value

0.003, **Supplementary Table S8**, **Figure 5**) and time to graft loss with a deletion

228 mismatch in rs2174926 with HR 2.332 (95% CI: 1.145–4.752, P-value 0.020,

Supplementary Table S9, Figure 6). However, the P-values did not reach the level
 of statistical significance FDR <0.05.

Supplementary Tables S2–S5 summarize the results from adjusted Cox proportional hazards models for the 40 deletion-tagging variants separately for time to AR, late rejection, graft loss and overall survival. Supplementary Figures S4–S7 display the effect of quartiles of overall deletion mismatch sums on LT endpoints. No association was found between the quartiles of overall deletion mismatch sums and LT endpoints.

236

238 Expression quantitative trait loci analyses and regulatory element annotation

We searched public databases to obtain information about regulatory functions for deletion-tagging variants rs11985201, rs2342606, rs2174926, and rs1944862.

Table 4 shows the *cis*-eQTL results for deletion-tagging variants rs11985201,
rs2342606, rs1944862, and rs2174926 in the FIVEx and eQTLGen phase I databases.
Using FIVEx browser, we found rs2342606 to be associated with increased expression
levels of TMEM254 antisense RNA 1 (*TMEM252-AS1*) gene in several different
tissues. In eQTLGen phase I database, variant rs2342606 associated with altered
expression of following genes: *TMEM254*, *TMEM254-AS1*, *FAM22B*, *RP11-119F19.2*, *FAM213A*, *SFTPD*, *RP11-137H2.4*, and *RP11-506M13.3*.

In FIVEx, rs11985201 associated with decreased expression levels of olfactory receptor family 4 subunit C member 6 (*OR4C6*) protein coding gene in lateral collateral ligament tissue. In eQTLGen phase I browser, we found variant rs11985201 to be associated with decreased expression level of indoleamine 2,3-dioxygenase 1 (*IDO1*) gene in blood cells.

Regulome DB and HaploReg tools were utilized for identifying regulatory elements 253 (Table 5). Two of the variants, rs11985201 and rs2174926, got a high Regulome DB 254 255 rank and score, which are both prediction scores informing the quality of supporting evidence in literature for regulatory role of variants. Using HaploReg v4.2 database, 256 altered transcription factor regulatory motifs were found for variants rs11985201, 257 rs2174926, and rs1944862. Deletion-tagging variant rs11985201 associated with 258 alteration in zinc-finger transcription factor (INSM1) and nuclear transcription factor Y 259 (NF-Y). Deletion-tagging variant rs2174926 was found to affect the forkhead box J2 260 (Foxj2), forkhead box L1 (Foxl1), and forkhead box P1 (Foxp1) transcription factors. 261 Deletion-tagging variant rs1944862 associated with alteration in forkhead box A (Foxa) 262 and zinc finger and btb domain containing 33 (ZBTB33) transcription factors. 263

264

265 **DISCUSSION**

In the present study, we investigated the association between LT endpoints and genome-wide mismatches in 666 LT recipients-donor pairs. We inspected mismatches in missense variants changing the amino acid sequence of the encoded protein and, additionally, in 40 common deletion-tagging variants. In deletion analyses, deletiontagging variants rs11985201, rs2342606, rs2174926 and rs1944862 were associated
with an increased risk of negative LT outcomes and could be novel histocompatibility
factors in LT. However, the observed P-values did not pass FDR <0.05 level, hence
further validation is needed.

Genetic differences between recipients and donors have been identified as an 274 important factor in allograft rejection and has been a topic of active research over the 275 last decade^{11–13}. The importance of matching of HLA alleles has been well-established 276 in kidney and hematopoietic stem cell transplantations³¹. However, the importance of 277 HLA matching for LT recipients and donors remains controversial^{32–35}. A recent study 278 found that mismatch in HLA-A was associated with an increased risk of allograft loss 279 after LT³³ while another meta-analysis found a significant association between HLA-C 280 matching and increased risk of AR in LT³⁶. However, an study conducted by Muro et 281 al. indicates that HLA matching does not yield better LT outcomes and that poorer 282 HLA matching showed better allograft survival and decreased rejection incidence³⁴. In 283 the present study the HLA I class eplet matchings in certain deletion-tagging variants 284 associated with a higher risk of AR. However, the p-values did not reach the level of 285 statistical significance FDR <0.05. Studies investigating the importance of non-HLA 286 genetic factors in LT outcomes remain scarce. 287

Whole genome-wide incompatibility between recipient and donor has emerged as a 288 potential risk factor in kidney transplantation^{11–14}. A study conducted by Reindl-289 Schwaighofer et al. in 2019 demonstrated the effect of genome-wide genetic 290 291 incompatibility between recipients and donors on graft survival in kidney transplantation¹². The results indicated that mismatches in transmembrane and 292 293 secreted proteins were associated with an increased risk of graft loss independently of HLA¹². Markkinen *et al.* in 2022 reported that an increasing mismatch sum in 294 kidney-related proteins increased the risk of time to AR after kidney transplantation²⁵. 295 296 In the present study, we found statistically significant association between time to late 297 rejection and missense variant mismatches in all proteins group. The effect size, however, was small, suggesting limited practical application. 298

Another recent study found an association between kidney allograft rejection and genomic mismatch at *LIMS1* locus¹¹. The results published by Steers *et al.* in 2019

were not confirmed in the Finnish patients by Markkinen et al. who instead found an 301 association between AR and mismatch in deletions at the complement factor H related 302 protein (CFHR) locus²⁵. The present study did not find associations with LIMS or 303 CFHR deletions. Instead, we found associations between four other deletion-tagging 304 variants and outcomes of LT. All these results, together with those of HSCT⁹, suggest 305 that deletion mismatches in general predispose to graft incompatibility but 306 predominant deletions vary between transplant types and populations. Clearly, more 307 studies on the role of deletion mismatches and how they lead to higher rejection risk 308 309 are needed. We must note that LT differs from other transplantations as the liver has a tolerogenic microenvironment that enables it to regulate local immune responses³⁷ 310 that may result in a higher tolerance against immunogenetic incompatibility in LT as 311 312 compared to other transplantations.

Whenever a recipient receives an organ that possesses protein structures foreign to 313 314 the recipient due to e.g., common deletions, there is a possibility of an immune reaction that may lead to negative post-LT outcomes. Therefore, when a recipient with a 315 homozygous deletion receives a liver from a donor lacking the particular homozygous 316 deletion, the immune system of the recipient identifies these protein structures on the 317 liver as foreign and causes the production of DSAs that may mitigate antibody-318 mediated rejection. In addition, the lack of certain important immune regulatory 319 proteins, such as CFHR1 may have a negative effect by itself. 320

Furthermore, genetic variants, and deletions as well, can regulate expression levels 321 of genes that can be located close to or at longer distances to the variant. These eQTL 322 323 effects can be screened from public databases. rs11985201 tags the deletion of metallopeptidase ADAM3A and ADAM5P pseudogenes. However, neither ADAM3A 324 or ADAM5P are expressed in liver^{38,39}. In addition, the variant affects binding motifs 325 for INSM and NF-Y factors downregulates IDO1 expression. rs2342606 tags the 326 327 deletion of LOC642521/LOC642538 genes but does not affect any known binding motifs. There is a limited information on these genes, but the LOC642521 seems to 328 329 be linked with a nuclear DNA-binding protein⁴¹. Variants rs11985201 and rs1944862 were included in the top 15,000 methylation guantitative train loci identified in human 330 331 liver⁴², meaning that they are associated with DNA methylation – a process that can change the activity of certain DNA regions by either inhibiting or promoting the activity 332 of transcription factors. 333

Strengths and limitations of the study may be observed. To be able to collect a 334 reasonable cohort size from a single center, the LTs in the present study are from a 335 relatively long period, extending 19 years in total. We compensated this potential effect 336 by selecting the transplantation year as one of the covariates. The size of the cohort 337 albeit one of the largest published so far for genome analyses included only 666 338 recipient-donor pairs, which enables the recognition of only relatively large effect sizes 339 for the p-values to pass the correction for multiple comparisons. Larger collaborative 340 studies are warranted to overcome the power issue. This study is the first large-scale 341 342 single-center study investigating the impact of genome-wide compatibility on time to AR, late rejection, graft loss and overall survival in LT. Single-center study in the 343 relatively homogeneous Finnish population should limit heterogeneity in patient 344 demographics, treatments, and genetic background. In addition, the recipients were 345 not affected by immunization from or treatments of previous liver allografts as only the 346 347 first LTs were included in the study cohort.

In conclusion, genetic incompatibility between recipients and donors on a wholegenome level may be a significant histocompatibility factor affecting LT outcomes.
Robust large-scale studies are required to confirm the role of genome-wide
mismatches and common variants in LTs.

352

353 AUTHOR CONTRIBUTION

MS, SM, JP, KH designed the study. MS and KH carried out the genome data

analysis. VL, FÅ, AN, MF provided clinical data and clinical expertise. MS, SM, JP,

FÅ, KH interpreted the results. MS and VL drafted the manuscript. All authors read,

accepted and contributed to the final version of the manuscript.

358

359 ACKNOWLEDGEMENTS

360 The reference data for genotype imputation was obtained from THL Biobank (study

number: BB2019_12). We thank all study participants for their generous participation

in biobank research.

364 DISCLOSURE AND FUNDING

- The authors of this manuscript have no conflicts of interest to disclose.
- 366 The study was partially supported by funding from the Government of Finland VTR
- ³⁶⁷ funding (to FRCBS). FÅ received grants from Mary and Georg Ehrnrooth Foundation
- 368 and Medicinska Understödsföreningen Liv och Hälsa.

369

370 SUPPORTING INFORMATION STATEMENT

371 Supplementary information may be found online.

373 **REFERENCES**

- ELTR. Evolution of LTs in Europe European Liver Transplant Registry.
 Accessed May 24, 2024. http://www.eltr.org/spip.php?article152
- Jadlowiec CC, Morgan PE, Nehra AK, et al. Not All Cellular Rejections Are the
 Same: Differences in Early and Late Hepatic Allograft Rejection. *Liver Transplant*. 2019;25(3):425-435. doi:10.1002/LT.25411
- O'Leary JG, Cai J, Freeman R, et al. Proposed Diagnostic Criteria for Chronic
 Antibody-Mediated Rejection in Liver Allografts. *Am J Transplant*.
 2016;16(2):603-614. doi:10.1111/AJT.13476
- Vionnet J, Miquel R, Abraldes JG, et al. Non-invasive alloimmune risk
 stratification of long-term liver transplant recipients. *J Hepatol.* 2021;75(6):1409-1419. doi:10.1016/j.jhep.2021.08.007
- Watt KDS, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution
 of Causes and Risk Factors for Mortality Post Liver Transplant: Results of the
 NIDDK Long Term Follow-up Study. *Am J Transplant*. 2010;10(6):1420.
 doi:10.1111/J.1600-6143.2010.03126.X
- Charlton M, Levitsky J, Aqel B, et al. International Liver Transplantation
 Society Consensus Statement on Immunosuppression in Liver Transplant
 Recipients. *Transplantation*. 2018;102(5):727-743.
 doi:10.1097/TP.00000000002147
- Fürst D, Müller C, Vucinic V, et al. High-resolution HLA matching in
 hematopoietic stem cell transplantation: a retrospective collaborative analysis.
 Blood. 2013;122(18):3220-3229. doi:10.1182/BLOOD-2013-02-482547
- Teven S, Akemoto KT, Erasaki AIT, Jertson AWG, Ichael JM, Ecka C. Twelve Years' Experience with National Sharing of HLA-Matched Cadaveric Kidneys for Transplantation. *http://dx.doi.org/101056/NEJM200010123431504*.
 2009;343(15):1078-1084. doi:10.1056/NEJM200010123431504
- McCarroll SA, Bradner JE, Turpeinen H, et al. Donor-recipient mismatch for
 common gene deletion polymorphisms in graft-versus-host disease. *Nat Genet*. 2009;41(12):1341-1344. doi:10.1038/ng.490
- 10. Ritari J, Hyvärinen K, Koskela S, et al. Computational Analysis of HLApresentation of Non-synonymous Recipient Mismatches Indicates Effect on the
 Risk of Chronic Graft-vs.-Host Disease after Allogeneic HSCT. *Front Immunol.*2019;10(JULY). doi:10.3389/fimmu.2019.01625
- 407 11. Steers NJ, Li Y, Drace Z, et al. Genomic Mismatch at LIMS1 Locus and
 408 Kidney Allograft Rejection . *N Engl J Med*. 2019;380(20):1918-1928.
 409 doi:10.1056/nejmoa1803731
- Reindl-Schwaighofer R, Heinzel A, Kainz A, et al. Contribution of non-HLA
 incompatibility between donor and recipient to kidney allograft survival:
 genome-wide analysis in a prospective cohort. *Lancet.* 2019;393(10174):910917. doi:10.1016/S0140-6736(18)32473-5
- 13. Mesnard L, Muthukumar T, Burbach M, et al. Exome Sequencing and

Prediction of Long-Term Kidney Allograft Function. PLoS Comput Biol. 415 2016;12(9):e1005088. doi:10.1371/journal.pcbi.1005088 416 Pineda S, Sigdel TK, Chen J, Jackson AM, Sirota M, Sarwal MM. Novel non-14. 417 histocompatibility antigen mismatched variants improve the ability to predict 418 antibody-mediated rejection risk in kidney transplant. Front Immunol. 419 2017;8(DEC):1687. doi:10.3389/FIMMU.2017.01687 420 Zhang Z, Menon MC, Zhang W, et al. Genome-wide non-HLA donor-recipient 15. 421 422 genetic differences influence renal allograft survival via early allograft fibrosis. Kidney Int. 2020;98(3):758-768. doi:10.1016/j.kint.2020.04.039 423 16. Balan V, Ruppert K, Demetris AJ, et al. Long-term outcome of human 424 leukocyte antigen mismatching in liver transplantation: Results of the national 425 institute of diabetes and digestive and kidney diseases liver transplantation 426 database. Hepatology. 2008;48(3):878-888. doi:10.1002/HEP.22435 427 17. Navarro VJ, Herrine S, Katopes C, Colombe B, Spain CV. The effect of HLA 428 class I (A and B) and class II (DR) compatibility on liver transplantation 429 outcomes: An analysis of the OPTN database. Liver Transplant. 430 2006;12(4):652-658. doi:10.1002/LT.20680 431 18. Thomson AW, Vionnet J, Sanchez-Fueyo A. Understanding, predicting and 432 433 achieving liver transplant tolerance: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2020;17(12):719-739. doi:10.1038/s41575-020-0334-4 434 19. Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver 435 allograft rejection: an international consensus document. Hepatology. 436 437 1997;25(3):658-663. doi:10.1002/HEP.510250328 438 20. Pärn K, Fontarnau JN, Isokallio MA, et al. Genotyping chip data lift-over to reference genome build GRCh38/hg38. Accessed July 4, 2022. 439 https://www.protocols.io/view/genotyping-chip-data-lift-over-to-reference-440 genome-n2bvjmbpvk5w/v2?version_warning=no 441 21. Pärn K, Isokallio MA, Fontarnau JN, Palotie A, Ripatti S, Palta P. Genotype 442 Imputation Workflow v3.0 V.2.; 2019. https://www.protocols.io/view/genotype-443 imputation-workflow-v3-0-xbgfijw?step=4&comment id=86624 444 Ritari J, Hyvärinen K, Clancy J, FinnGen, Partanen J, Koskela S. Increasing 22. 445 accuracy of HLA imputation by a population-specific reference panel in a 446 FinnGen biobank cohort. NAR genomics Bioinforma. 2020;2(2):Iqaa030. 447 doi:10.1093/nargab/lgaa030 448 23. Duquesnoy RJ, Askar M. HLAMatchmaker: A Molecularly Based Algorithm for 449 Histocompatibility Determination. V. Eplet Matching for HLA-DR, HLA-DQ, and 450 HLA-DP. Hum Immunol. 2007;68(1):12-25. 451 doi:10.1016/J.HUMIMM.2006.10.003 452 24. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. 453 Genome Biol. 2016;17(1):1-14. doi:10.1186/S13059-016-0974-4/TABLES/8 454 Markkinen S, Helanterä I, Lauronen J, Lempinen M, Partanen J, Hyvärinen K. 455 25. Mismatches in Gene Deletions and Kidney-related Proteins as Candidates for 456 Histocompatibility Factors in Kidney Transplantation. Kidney Int reports. 457

- 458 2022;7(11):2484-2494. doi:10.1016/J.EKIR.2022.08.032
- 459 26. Kwong A, Boughton AP, Wang M, et al. FIVEx: an interactive eQTL browser
 460 across public datasets. *Bioinformatics*. 2022;38(2):559.
 461 doi:10.1093/BIOINFORMATICS/BTAB614
- Võsa U, Claringbould A, Westra HJ, et al. Large-scale cis- and trans-eQTL
 analyses identify thousands of genetic loci and polygenic scores that regulate
 blood gene expression. *Nat Genet 2021 539*. 2021;53(9):1300-1310.
 doi:10.1038/S41588-021-00913-Z
- Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in
 personal genomes using RegulomeDB. *Genome Res.* 2012;22(9):1790.
 doi:10.1101/GR.137323.112
- Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states,
 conservation, and regulatory motif alterations within sets of genetically linked
 variants. *Nucleic Acids Res.* 2012;40(Database issue):D930.
 doi:10.1093/NAR/GKR917
- 30. R Core Team. A Language and Environment for Statistical Computing. R
 Foundation for Statistical Computing, Vienna. References Scientific
 Research Publishing. Published 2022. Accessed January 8, 2024.
 https://www.scirp.org/reference/referencespapers?referenceid=3456808
- 477 31. Opelz G, Wujciak T, Döhler B, Scherer S, Mytilineos J. HLA compatibility and
 478 organ transplant survival. Collaborative Transplant Study. *Rev Immunogenet*.
 479 1999;1(3):334-342. Accessed August 6, 2023.
 480 https://europepmc.org/article/med/11256424
- 32. Balan V, Ruppert K, Demetris AJ, et al. Long-term outcome of human
 leukocyte antigen mismatching in liver transplantation: results of the National
 Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation
 Database. *Hepatology*. 2008;48(3):878-888. doi:10.1002/HEP.22435
- Bricogne C, Halliday N, Fernando R, et al. Donor–recipient human leukocyte
 antigen A mismatching is associated with hepatic artery thrombosis, sepsis,
 graft loss, and reduced survival after liver transplant. *Liver Transplant*.
 2022;28(8):1306-1320. doi:10.1002/LT.26458
- 489 34. Muro M, López-Álvarez MR, Campillo JA, et al. Influence of human leukocyte 490 antigen mismatching on rejection development and allograft survival in liver 491 transplantation: Is the relevance of HLA-A locus matching being 492 underestimated? *Transpl Immunol*. 2012;26(2-3):88-93.
 493 doi:10.1016/J.TRIM.2011.11.006
- Muro M, Legaz I. Importance of human leukocyte antigen antibodies and
 leukocyte antigen/killer-cell immunoglobulin-like receptor genes in liver
 transplantation. *World J Gastroenterol*. 2023;29(5):766-772.
 doi:10.3748/WJG.V29.I5.766
- 498 36. Kok G, Ilcken EF, Houwen RHJ, et al. The Effect of Genetic HLA Matching on
 499 Liver Transplantation Outcome: A Systematic Review and Meta-Analysis. Ann
 500 Surg Open. 2023;4(3):e334. doi:10.1097/AS9.0000000000334

- 37. Demetris AJ, Bellamy COC, Gandhi CR, Prost S, Nakanuma Y, Stolz DB.
 Functional Immune Anatomy of the Liver—As an Allograft. *Am J Transplant*.
 2016;16(6):1653-1680. doi:10.1111/AJT.13749
- 38. AGCOH. ADAM3A (ADAM metallopeptidase domain 3A (pseudogene)).
 Published June 1, 2014. Accessed October 6, 2023.
 https://atlasgeneticsoncology.org/gene/53975/adam3a-(adam-
- 507 metallopeptidase-domain-3a-(pseudogene))/
- 39. AGCOH. ADAM5 (ADAM metallopeptidase domain 5 (pseudogene)).
 Published November 1, 2014. Accessed October 6, 2023.
 https://atlasgeneticsoncology.org/gene/60138/
- 40. Lichtinghagen R, Michels D, Haberkorn CI, et al. Matrix metalloproteinase
 (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely
 related to the fibroproliferative process in the liver during chronic hepatitis C. J *Hepatol.* 2001;34(2):239-247. doi:10.1016/S0168-8278(00)00037-4
- Seno A, Kasai T, Ikeda M, et al. Characterization of Gene Expression Patterns
 among Artificially Developed Cancer Stem Cells Using Spherical SelfOrganizing Map. *Cancer Inform.* 2016;15:163. doi:10.4137/CIN.S39839
- 42. Bonder MJ, Kasela S, Kals M, et al. Genetic and epigenetic regulation of gene
 expression in fetal and adult human livers. *BMC Genomics*. 2014;15(1).
 doi:10.1186/1471-2164-15-860

521

523 FIGURE LEGENDS

Figure 1. Flow of the study population. Enrolling and exclusion of the liver transplantation recipients and donors. DNA, deoxyribonucleic acid; QC, quality control.

527 **Figure 2. Flow of genetic variants.** HLA, human leukocyte antigen; MHC, major 528 histocompatibility complex.

Figure 3. Kaplan-Meier plot displaying the effect of deletion-tagging variant 529 rs11985201 mismatch on acute rejection-free survival. The blue curve represents 530 the 'deletion mismatch' group with recipients who were homozygous for a deletion-531 tagging allele G and received a transplant from a donor with TG or TT. The orange 532 533 curve represents the 'no mismatch' group. Under the survival curve, a risk table is displayed with the number of recipients at risk of acute rejection. The presented hazard 534 ratio, confidence intervals and P-value were calculate using Cox proportional hazards 535 model. The model was adjusted with recipient and donor age, recipient and donor sex, 536 cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of 537 transplantation, autoimmune liver disease and initial calcineurin inhibitor type. 538 Deletion-tagging variant: rs11985201, Affected genes: ADAM metallopeptidase 539 domain 3A (pseudogene) and domain 5 (pseudogene) (ADAM3A/ADAM5P). Cl, 540 confidence interval; HR, hazard ratio. 541

Figure 4. Kaplan-Meier plot displaying the effect of deletion-tagging variant 542 rs2342606 mismatch on acute rejection-free survival. The blue curve represents 543 the 'deletion mismatch' group with recipients who were homozygous for a deletion-544 tagging allele T and received a transplant from a donor with TC or CC. The orange 545 curve represents the 'no mismatch' group. Under the survival curve, a risk table is 546 displayed with the number of recipients at risk of acute rejection. The presented hazard 547 ratio, confidence intervals and P-value were calculate using Cox proportional hazards 548 549 model. The model was adjusted with recipient and donor age, recipient and donor sex, cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of 550 transplantation, autoimmune liver disease and initial calcineurin inhibitor type. Affected 551 genes: C1D nuclear receptor corepressor pseudogene 3 (LOC642521) and C1D 552 553 nuclear receptor corepressor pseudogene 2 (LOC642538). CI, confidence interval; HR, hazard ratio. 554

555

Figure 5. Kaplan-Meier plot displaying the effect of deletion-tagging variant 556 rs1944862 mismatch on graft loss-free survival. The blue curve represents the 557 'deletion mismatch' group with recipients who were homozygous for a deletion-tagging 558 559 allele A and received a transplant from a donor with AG or GG. The orange curve 560 represents the 'no mismatch' group. Under the survival curve, a risk table is displayed with the number of recipients at risk of late rejection. The presented hazard ratio, 561 confidence intervals and P-value were calculate using Cox proportional hazards 562 model. The model was adjusted with recipient and donor age, recipient and donor sex, 563 cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of 564 transplantation, autoimmune liver disease and initial calcineurin inhibitor type. Affected 565

566 gene: olfactory receptor family 4 subunit (OR4P1P), pseudogene,. CI, confidence 567 interval; HR, hazard ratio.

Figure 6. Kaplan-Meier plot displaying the effect of deletion-tagging variant rs2174926 mismatch on graft loss-free survival. The blue curve represents the 'deletion mismatch' group with recipients who were homozygous for a deletion-tagging allele A and received a transplant from a donor with AG or GG. The orange curve represents the 'no mismatch' group. Under the survival curve, a risk table is displayed with the number of recipients at risk of graft loss. The presented hazard ratio, confidence intervals and P-value were calculate using Cox proportional hazards model. The model was adjusted with recipient and donor age, recipient and donor sex, cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of transplantation, autoimmune liver disease and initial calcineurin inhibitor type. Affected gene: hypothetical protein (LOC442434). CI, confidence interval; HR, hazard ratio.

| Characteristic | All recipients | Rejection | No rejection | P * | Late rejection | No late rejection | P * |
|---|----------------|---------------|---------------|---------------------|----------------|-------------------|--------------------|
| n (%) | 666 (100) | 277 (42) | 389 (58) | | 97 (15) | 569 (85) | |
| Age (median, range) | 54 (18–74) | 52 (18–73) | 55 (18–74) | <0.001ª | 52 (18–73) | 54 (45–61) | 0.027 ^a |
| Gender, n (%) | | | | 0.029 ^b | | | 0.135ª |
| Male | 359 (54) | 135 (49) | 224 (58) | | 45 (46) | 314 (55) | |
| Female | 307 (46) | 142 (51) | 165 (42) | | 52 (54) | 255 (45) | |
| Primary indication, n (%) | | | | | | | |
| Primary sclerosing cholangitis | 128 (19) | 65 (23) | 63 (16) | 0.024 ^b | 21 (22) | 107 (19) | 0.605 ^b |
| Alcoholic cirrhosis | 124 (19) | 29 (10) | 95 (24) | <0.001 ^b | 10 (10) | 114 (20) | 0.033 ^b |
| Hepatocellular carcinoma and cirrhosis | 80 (12) | 28 (10) | 52 (13) | 0.248 ^b | 7 (7) | 73 (13) | 0.161 ^b |
| Primary biliary cirrhosis | 53 (8) | 27 (10) | 26 (7) | 0.120 ^b | 11 (11) | 42 (7) | 0.259 ^b |
| Cryptogenic (unknown) cirrhosis | 41 (6) | 13 (5) | 28 (7) | 0.245 ^b | 6 (6) | 35 (6) | 1 ^b |
| NASH | 28 (4) | 3 (1) | 25 (6) | 0.001 ^b | 2 (2) | 26 (5) | 0.388 ^b |
| Autoimmune cirrhosis | 28 (4) | 11 (4) | 17 (4) | 0.955 ^b | 5 (5) | 23 (4) | 0.817 ^b |
| Polycystic disease | 20 (3) | 7 (3) | 13 (3) | 0.706 ^b | 2 (2) | 18 (3) | 0.790 ^b |
| Other | 164 (25) | 94 (34) | 70 (18) | <0.001 ^b | 33 (34) | 131 (23) | 0.028 ^b |
| Autoimmune liver disease, n (%) | 223 (33) | 109 (39) | 114 (29) | 0.009 ^b | 37 (38) | 186 (33) | 0.349 ^b |
| Transplantation year | | | | | | | |
| 2000–2005 | 126 (19) | 66 (24) | 60 (15) | 0.009 ^b | 19 (20) | 107 (19) | 0.967 ^b |
| 2006–2011 | 208 (31) | 89 (32) | 119 (31) | 0.736 ^b | 39 (40) | 169 (30) | 0.052 ^b |
| 2012–2018 | 332 (50) | 122 (44) | 210 (54) | 0.014 ^b | 39 (40) | 293 (51) | 0.052 ^b |
| Calcineurin inhibitor, n (%) | | | | 0.436 ^b | | | 0.193 ^b |
| Cyclosporine | 545 (82) | 232 (84) | 313 (80) | | 85 (88) | 460 (81) | |
| Tacrolimus | 108 (16) | 41 (15) | 67 (17) | | 11 (11) | 97 (17) | |
| Data not available | 13 (2) | 4 (1) | 9 (2) | | 1 (1) | 12 (2) | |
| | | | | Median (IQR) | | | |
| Follow–up time ^c , months | 82 (43–145) | 97 (50–154) | 73 (39–131) | 0.002 ^a | 91 (51–149) | 79 (41–141) | 0.103 ^a |
| Cold ischemia time, minutes | 298 (258–357) | 297 (257–336) | 302 (263–366) | 0.104 ^a | 298 (259–337) | 300 (258–359) | 0.671ª |

Table 1. Characteristics of the study population for acute and late rejection groups.

| HLA eplet mismatch sum | 27 (21–33) | 29 (23–34) | 26 (20–32) | 0.002 ^a | 29 (24–35) | 27 (21–33) | 0.026 ^a |
|---------------------------|------------|------------|------------|--------------------|------------|------------|--------------------|
| HLA I eplet mismatch sum | 17 (12–22) | 17 (13–22) | 16 (12–21) | 0.022ª | 18 (13–21) | 17 (12–22) | 0.126ª |
| HLA II eplet mismatch sum | 10 (7–14) | 11 (7–14) | 10 (7–13) | 0.032 ^a | 11 (8–15) | 10 (7–13) | 0.107 ^a |

599 HLA, human leukocyte antigen; IQR, interquartile range, NASH non-alcoholic steatohepatitis

⁶⁰⁰ *The significance of variation was calculated between the outcome groups.

^aThe Mann–Whitney U-test.

⁶⁰² ^bThe Pearson chi-square test

⁶⁰³ ^cIncludes time to last follow-up date, re-transplantation and death.

604

| Characteristic | All recipients | Graft loss | No graft loss | P * | Deceased | Alive | P * |
|---|----------------|---------------|---------------|---------------------|---------------|---------------|---------------------|
| n (%) | 666 (100) | 42(6) | 624 (94) | | 163 (24) | 503 (76) | |
| Age (median, range) | 54 (18–74) | 50 (18–64) | 54 (18–743) | 0.007 ^a | 58 (18–74) | 52 (18–73) | <0.001ª |
| Gender, n (%) | | | | 0.494 ^b | | | 0.543 ^b |
| Male | 359 (54) | 20 (48) | 339 (54) | | 84 (52) | 275 (55) | |
| Female | 307 (46) | 22 (52) | 285 (46) | | 79 (48) | 228 (45) | |
| Primary indication, n (%) | | | | | | | |
| Primary sclerosing cholangitis | 128 (19) | 12 (29) | 116 (19) | 0.166 ^b | 23 (14) | 105 (21) | 0.073 ^b |
| Alcoholic cirrhosis | 124 (19) | 3 (7) | 121 (19) | 0.077 ^b | 26 (16) | 98 (19) | 0.373 ^b |
| Hepatocellular carcinoma and cirrhosis | 80 (12) | 2 (5) | 78 (13) | 0.212 ^b | 25 (15) | 55 (11) | 0.173 ^b |
| Primary biliary cirrhosis | 53 (8) | 5 (12) | 48 (8) | 0.495 ^b | 11 (7) | 42 (8) | 0.624 ^b |
| Cryptogenic (unknown) cirrhosis | 41 (6) | 3 (7) | 38 (6) | 1 ^b | 16 (10) | 25 (5) | 0.040 ^b |
| NASH | 28 (4) | 0 (0) | 28 (4) | 0.315 ^b | 7 (4) | 21 (4) | 1 ^b |
| Autoimmune cirrhosis | 28 (4) | 1 (2) | 27 (4) | 0.833 ^b | 7 (4) | 21 (4) | 1 ^b |
| Polycystic disease | 20 (3) | 0 (0) | 20 (3) | 0.477 ^b | 2 (1) | 18 (4) | 0.206 ^b |
| Other | 164 (25) | 16 (38) | 148 (24) | 0.056 ^b | 46 (28) | 118 (23) | 0.262 ^b |
| Autoimmune liver disease, n (%) | 223 (33) | 20 (48) | 203 (33) | 0.066 ^b | 48 (29) | 175 (35) | 0.246 ^b |
| Transplantation year | | | | | | | |
| 2000–2005 | 126 (19) | 12 (29) | 114 (18) | 0.148 ^b | 51 (32) | 75 (15) | <0.001 ^b |
| 2006–2011 | 208 (31) | 15 (36) | 193 (31) | 0.634 ^b | 58 (36) | 150 (30) | 0.200 ^b |
| 2012–2018 | 332 (50) | 15 (36) | 317 (51) | 0.083 ^b | 54 (33) | 278 (55) | <0.001 ^b |
| Calcineurin inhibitor, n (%) | | | | 0.071 ^b | | | 0.393 ^b |
| Cyclosporine | 545 (82) | 38 (90) | 507 (81) | | 135 (83) | 410 (82) | |
| Tacrolimus | 108 (16) | 2 (5) | 106 (17) | | 22 (13) | 86 (17) | |
| Data not available | 13 (2) | 2 (5) | 11 (2) | | 6 (4) | 7 (1) | |
| | | | | Median (IQR) | | | |
| Follow–up time ^c , months | 82 (43–145) | 34(4–77) | 88 (47–147) | <0.001 ^a | 39 (13–103) | 93 (55–150) | <0.001 ^a |
| Cold ischemia time, minutes | 298 (258–357) | 284 (253–342) | 299 (258–359) | 0.573 ^a | 316 (267–375) | 294 (257–345) | 0.013 ^a |

Table 2. Characteristics of the study population for graft loss and overall survival groups.

| HLA eplet mismatch sum | 27 (21–33) | 27 (21–32) | 27 (21–33) | 0.857 ^a | 27 (21–35) | 27 (21–33) | 0.812 ^a |
|---------------------------|------------|------------|------------|--------------------|------------|------------|--------------------|
| HLA I eplet mismatch sum | 17 (12–22) | 17 (11–21) | 17 (12–22) | 0.443 ^a | 17 (12–23) | 17 (12–21) | 0.588 ^a |
| HLA II eplet mismatch sum | 10 (7–14) | 10 (7–14) | 10 (7–14) | 0.649 ^a | 10 (7–14) | 10 (7–14) | 0.895 ^a |

607 HLA, human leukocyte antigen; IQR, interquartile range, NASH non-alcoholic steatohepatitis

⁶⁰⁸ *The significance of variation was calculated between the outcome groups.

609 ^aThe Mann–Whitney U-test.

610 ^bThe Pearson chi-square test

⁶¹¹ ^cIncludes time to last follow-up date, re-transplantation and death.

Table 3. Summary statistics of adjusted Cox proportional hazards models for four different missense variant groups.

| | | Cox proportional hazards model | | | | | | |
|--------------------|--|--------------------------------|---------|-------------------------|---------|--|--|--|
| Endpoint | Missense variants | Sum of mismate | ches | Quartiles of mismatches | | | | |
| | | HR (95% CI) | P-value | HR (95% CI) | P-value | | | |
| | All proteins | 1.000(0.999–1.001) | 0.891 | 1.003(0.900-1.118) | 0.956 | | | |
| Time to acute | Transmembrane and secreted proteins | 1.000(0.998–1.002) | 0.820 | 1.041(0.934–1.161) | 0.466 | | | |
| rejection | Transmembrane proteins | 1.000(0.998–1.002) | 0.787 | 1.021(0.916–1.138) | 0.708 | | | |
| | Liver-related proteins | 0.999(0.995–1.003) | 0.484 | 0.985(0.883–1.099) | 0.791 | | | |
| | All proteins | 0.998(0.996-0.999) | 0.011 | 0.812(0.674–0.977) | 0.028 | | | |
| Time to late | Transmembrane and secreted proteins | 0.997(0.994–1.000) | 0.070 | 0.890(0.740–1.071) | 0.218 | | | |
| rejection | Transmembrane proteins | 0.997(0.993–1.001) | 0.130 | 0.859(0.714–1.034) | 0.109 | | | |
| | Liver-related proteins | 0.994(0.987–1.001) | 0.122 | 0.937(0.779–1.127) | 0.489 | | | |
| | All proteins | 0.999(0.997-1.002) | 0.657 | 0.866(0.649–1.156) | 0.329 | | | |
| Time to graft loss | Transmembrane and secreted proteins | 0.996(0.991–1.001) | 0.164 | 0.747(0.559–1.000) | 0.050 | | | |
| - | Transmembrane proteins | 0.995(0.989–1.001) | 0.125 | 0.740(0.551–0.994) | 0.046 | | | |
| | Liver-related proteins | 1.006(0.995–1.016) | 0.297 | 1.163(0.869–1.556) | 0.309 | | | |
| | All proteins | 0.999(0.998–1.001) | 0.226 | 0.907(0.784–1.049) | 0.189 | | | |
| Overall survival | Transmembrane and secreted proteins | 0.999(0.996–1.001) | 0.358 | 0.897(0.777–1.036) | 0.138 | | | |
| | Transmembrane proteins | 0.999(0.996–1.002) | 0.647 | 0.934(0.809–1.077) | 0.348 | | | |
| | Liver-related proteins | 0.997(0.991-1.002) | 0.271 | 0.956(0.828-1.105) | 0.546 | | | |

615 MHC region and sex chromosomes excluded. CI, confidence interval; HR, hazard ratio.

Models were adjusted with donor and recipient age, donor and recipient sex, cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of transplantation, autoimmune liver disease and initial calcineurin inhibitor type.

619

620

621

623 4. *cis*-eQTL results of deletion-tagging variants rs11985201, rs2342606, rs2174926, 624 and rs1944862.

| | FIVEx | | | | | | |
|------------|--------------|--------------------|---------------|-------------|---|---------------------|--|
| Variant | CHR:POS | Assessed allele | Gene | Effect size | P-value | Tissue | |
| rs2342606 | 10:80034407 | т | TMEM254-AS1 | 0.18–0.56 | 1.38x10 ⁻²⁵ – 5.89x10 ⁻⁸ | Multiple tissues | |
| rs1944862 | 11:55521460 | G | OR4C6 | -0.47 | 9.12x10 ⁻¹³ | LCL | |
| rs11985201 | NA | NA | NA | NA | NA | NA | |
| rs2174926 | NA | NA | NA | NA | NA | NA | |
| | | | eQTLGen | phase I | | | |
| Variant | CHR:POS | Assessed allele | Gene | Z-score | P-value | Tissue | |
| rs11985201 | 8: 39772878 | А | IDO1 | -5.10 | 3.32x10 ⁻⁷ | Blood | |
| rs2342606 | 10:81845357 | Т | TMEM254 | -20.46 | 4.89x10 ⁻⁹³ | Blood | |
| rs2342606 | 10:81822642 | Т | TMEM254-AS1 | -16.80 | 2.49x1063 | Blood | |
| rs2342606 | 10: 81468710 | Т | FAM22B | 10.78 | 4.18 x10 ⁻²⁷ | Blood | |
| rs2342606 | 10: 81474464 | Т | RP11-119F19.2 | 8.44 | 3.13 x10 ⁻¹⁷ | Blood | |
| rs2342606 | 10: 82180169 | Т | FAM213A | 7.97 | 1.65 x10 ⁻¹⁵ | Blood | |
| rs2342606 | 10: 81719933 | Т | SFTPD | -7.88 | 3.29 x10 ⁻¹⁵ | Blood | |
| rs2342606 | 10: 82292525 | Т | RP11-137H2.4 | -5.15 | 2.66 x10 ⁻⁷ | Blood | |
| rs2342606 | 10: 81428750 | Т | RP11-506M13.3 | 4.95 | 7.38 x10 ⁻⁷ | Blood | |
| rs1944862 | NA | NA | NA | NA | NA | Blood | |
| rs2174926 | NA | NA | NA | NA | NA | Blood | |

625 CHR, chromosome; eQTL, expression quantitative loci; LCL, lateral collateral ligament; NA, 626 not available; POS, position.

641 **Table 5. Identification of regulatory elements.**

| | Deletion- tagging variant | Deletion- tagging Deleted gene variant | | ome DBª | HaploReg⁵ | |
|---------------------------------|---|---|------------------------------|-----------------------------------|--|--|
| | | | Rank | Score | Regulatory motifs altered | |
| | rs11985201 rs2342606 rs2174926 rs1944862 | ADAM3A/ADAM5P LOC642521/LOC642538 LOC442434 OR4P1P | 1b 6 1f 6 | 0.710 0.285 0.897 0.187 | INSM1, NF-Y NA Foxj2, Foxl1, Foxp1 Foxa, ZBTB33 | |
| 642 | NA, not avail | able. | | | | |
| 643 644 645 646 647 | ªRegulome D [♭] HaploReg v₄ | B, <u>https://www.regulomedb.o</u> 4.2, <u>https://pubs.broadinstitute</u> | rg/regulome-s e.org/mamma | <u>search</u> Is/haploreg/hapl | oreg.php | |
| 648 | | | | | | |
| 649 | | | | | | |
| 650 | | | | | | |
| 651 | | | | | | |
| 652 | | | | | | |
| 653 | | | | | | |
| 654 | | | | | | |
| 655 | | | | | | |
| 656 | | | | | | |
| 657 | | | | | | |
| 658 | | | | | | |
| 659 | | | | | | |
| 660 | | | | | | |
| 661 | | | | | | |
| 662 | | | | | | |
| 663 | | | | | | |
| 664 | | | | | | |
| 665 | | | | | | |
| 666 | | | | | | |
| 667 | | | | | | |





Figure 1. Flow of the study population. Enrolling and exclusion of the liver transplantation

671 recipients and donors. DNA, deoxyribonucleic acid; QC, quality control.

672





Figure 2. Flow of genetic variants. HLA, human leukocyte antigen; MHC, major 677 histocompatibility complex.





696



Figure 4. Kaplan-Meier plot displaying the effect of deletion-tagging variant rs2342606 mismatch
 on acute rejection-free survival.

700

697





705



Figure 6. Kaplan-Meier plot displaying the effect of deletion-tagging variant rs2174926 mismatch
 on graft loss-free survival.